Rethinking prescribing in the United States

摘要

Spending on prescription drags is rising rapidly in the United States The United States Is exploring ways to subsidise drug costs for all senior citizens, many of whom have no insurance for prescription drugs Limited lists of medicines are increasingly accepted as a way of controlling spending on drugs Reference pricing may be the best way to administer drug benefits while rewarding true pharmaceutical innovation Substantial methodological and political barriers exist-to the essential medicine and reference pricing approach.